364 related articles for article (PubMed ID: 27704357)
1. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Lin L; Wang G; Ming J; Meng X; Han B; Sun B; Cai J; Jiang C
Tumour Biol; 2016 Nov; 37(11):15333-15339. PubMed ID: 27704357
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C
PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Zhao XC; An P; Wu XY; Zhang LM; Long B; Tian Y; Chi XY; Tong DY
Tumour Biol; 2016 Jun; 37(6):7203-12. PubMed ID: 26666816
[TBL] [Abstract][Full Text] [Related]
6. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Roundabout4 predicts poor prognosis of primary glioma patients via correlating with microvessel density.
Cai H; Xue Y; Liu W; Li Z; Hu Y; Li Z; Shang X; Liu Y
J Neurooncol; 2015 May; 123(1):161-9. PubMed ID: 25859844
[TBL] [Abstract][Full Text] [Related]
8. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
9. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-584-3p, a novel tumor suppressor and prognostic marker, reduces the migration and invasion of human glioma cells by targeting hypoxia-induced ROCK1.
Xue H; Guo X; Han X; Yan S; Zhang J; Xu S; Li T; Guo X; Zhang P; Gao X; Liu Q; Li G
Oncotarget; 2016 Jan; 7(4):4785-805. PubMed ID: 26715733
[TBL] [Abstract][Full Text] [Related]
11. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of phosphatidylethanolamine-binding protein 4 (PEBP4) strongly associates with human gliomas grade.
Huang RQ; Shi DL; Huang W; Chen F; Lu YC
J Neurooncol; 2016 Apr; 127(2):235-42. PubMed ID: 26725095
[TBL] [Abstract][Full Text] [Related]
13. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.
Soritau O; Tomuleasa C; Aldea M; Petrushev B; Susman S; Gheban D; Ioani H; Cosis A; Brie I; Irimie A; Kacso G; Florian IS
J BUON; 2011; 16(2):282-9. PubMed ID: 21766499
[TBL] [Abstract][Full Text] [Related]
14. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Molnár P; Méhes G
Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
[TBL] [Abstract][Full Text] [Related]
15. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a side population of astrocytoma cells in response to temozolomide.
Chua C; Zaiden N; Chong KH; See SJ; Wong MC; Ang BT; Tang C
J Neurosurg; 2008 Nov; 109(5):856-66. PubMed ID: 18976075
[TBL] [Abstract][Full Text] [Related]
18. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
19. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
20. Stem cell markers in glioma progression and recurrence.
Hattermann K; Flüh C; Engel D; Mehdorn HM; Synowitz M; Mentlein R; Held-Feindt J
Int J Oncol; 2016 Nov; 49(5):1899-1910. PubMed ID: 27600094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]